Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (413)	4/2/1998 4:38:00 PM
From: Patrick A. Kelly	Read Replies (2) \| Respond to of 492

What web site? What (public and widely distributed or current) information? "I know nothing!" Col. K.

To: David Bogdanoff who wrote (413)	4/2/1998 4:45:00 PM
From: Yo Yo	Read Replies (1) \| Respond to of 492

David, I hope you and others can take my comments with a grain of salt. I am not knocking the company, just the current valuation. I want to buy a bunch of this stock. I just want to get a real good deal on it. Right now, I think it is pretty fairly valued. If Coffin is successful pumping up the price a bit, it will serve ABAX well for the long run. Bottom line is still to get market penetration and positive cash flow. Hemagen (HMGN:Nasdaq, $1 1/4) is currently doing due diligence on purchase of the Dade-Behring unit which they say IS profitable and currently has the lowest cost consumable. Their stock is getting beat up in part because of the uncertainty of their imminent purchase. Yo Yo